---
id: 032
title: Meropenem for Meningitis - Dosing and CNS Penetration
category: antimicrobials
subcategory: carbapenems
tags: [meropenem, meningitis, CNS-penetration, seizure-risk, imipenem]
difficulty: medium
---

## Question

Why is **meropenem preferred over imipenem** for bacterial meningitis? What is the appropriate dosing strategy?

## Answer

### **Meropenem vs Imipenem for Meningitis:**

| Feature | Meropenem | Imipenem |
|---------|-----------|----------|
| **CNS penetration** | 9-31% (variable) | 10-20% |
| **Seizure risk** | Low | **HIGH** (epileptogenic) |
| **GABA inhibition** | 20× less than imipenem | High (causes seizures) |
| **FDA approval for meningitis** | Yes | **NO** (contraindicated) |
| **Preferred carbapenem for CNS infections** | **YES** | NO |

### **Why Meropenem is Safer:**
- **Lower neurotoxicity:** Meropenem requires 20× higher concentration than imipenem to inhibit GABA receptors
- Imipenem's epileptogenic potential is especially problematic in children and patients with CNS disease
- Imipenem-cilastatin can cause seizures, myoclonus, encephalopathy

### **Meropenem Dosing for Meningitis:**

| Patient Population | Dose | Rationale |
|-------------------|------|-----------|
| **Standard meningitis** | 2g IV q8h | Standard dosing |
| **Ventriculitis/resistant organisms** | 2g IV q8h (extended infusion 3h) | ↑ CSF penetration |
| **Very high-dose strategy** | 8-12g/day continuous infusion | Target CSF >1-4 mg/L |

### **Key Dosing Principles:**
- **Higher doses needed** for adequate CSF levels (standard doses → only 1-2 mg/L CSF)
- **Extended or continuous infusion** improves CSF penetration
- Target: CSF concentration >MIC for causative organism

## Key Points

### **Indications for Meropenem in CNS Infections:**
- **Gram-negative meningitis:** *Pseudomonas*, Enterobacterales, *Acinetobacter*
- **Post-neurosurgical meningitis:** Broad coverage including resistant organisms
- **Carbapenem-resistant organisms:** May need even higher doses or combination therapy

### **Clinical Pearls:**
- **NOT first-line for *S. pneumoniae*** - use ceftriaxone ± vancomycin
- **Combination therapy:** Often combined with vancomycin (MRSA) or aminoglycoside (synergy)
- **Monitor:** Seizure activity, especially with high doses or renal impairment
- **CSF levels:** Variable (9-31% penetration) - consider therapeutic drug monitoring if available

## Sources

- [ScienceDirect: Meropenem CSF Penetration in Post-Neurosurgery Meningitis]
- [PMC6310956: CSF Penetration of Very High-Dose Meropenem]
- [JAC: Neurotoxicity of Carbapenem Antibiotics in Bacterial Meningitis]

## Media

N/A
